Your browser is no longer supported. Please, upgrade your browser.
Settings
SCPS [NASD]
Scopus BioPharma Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own2.50% Shs Outstand14.09M Perf Week-11.25%
Market Cap126.42M Forward P/E- EPS next Y-0.73 Insider Trans2.44% Shs Float8.97M Perf Month-21.31%
Income-10.90M PEG- EPS next Q-0.08 Inst Own0.30% Short Float0.32% Perf Quarter-49.09%
Sales- P/S- EPS this Y-338.30% Inst Trans- Short Ratio0.18 Perf Half Y-
Book/sh-0.13 P/B- EPS next Y-78.00% ROA-790.80% Target Price- Perf Year-
Cash/sh0.11 P/C70.23 EPS next 5Y- ROE728.00% 52W Range5.34 - 47.86 Perf YTD-48.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-83.97% Beta-
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low43.63% ATR0.68
Employees1 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)38.15 Volatility5.77% 8.09%
OptionableNo Debt/Eq- EPS Q/Q-147.40% Profit Margin- Rel Volume0.20 Prev Close7.57
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume158.97K Price7.67
Recom2.00 SMA20-14.78% SMA50-17.56% SMA200-32.18% Volume22,158 Change1.32%
Feb-16-21Initiated The Benchmark Company Speculative Buy $20
Mar-16-21 05:39AM  
Mar-15-21 07:00AM  
Feb-10-21 08:05PM  
Feb-08-21 07:00PM  
Jan-29-21 08:00PM  
Jan-27-21 09:20AM  
Jan-26-21 08:00PM  
Jan-19-21 07:00AM  
Dec-29-20 04:00AM  
Dec-18-20 12:12PM  
10:55AM  
Dec-17-20 12:23PM  
08:59AM  
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibson Robert JVice ChairmanFeb 25Buy9.291501,393300Feb 26 01:16 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 25Buy9.018007,2087,750Feb 26 01:21 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 24Buy9.453002,8356,950Feb 26 01:21 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 24Buy9.481151,09080,790Feb 26 01:21 PM
Gibson Robert JVice ChairmanFeb 24Buy9.461501,419150Feb 26 01:16 PM
Lamstein Joshua RChairmanFeb 23Buy9.345004,670117,297Feb 24 07:54 AM
Greenspan Ira ScottExecutive Committee ChairmanFeb 23Buy9.661,30012,5586,650Feb 24 07:46 AM
Greenspan Ira ScottExecutive Committee ChairmanFeb 23Buy9.582001,91680,675Feb 24 07:46 AM
Lamstein Joshua RChairmanFeb 22Buy9.99100999116,797Feb 23 08:04 AM
Greenspan Ira ScottExecutive Committee ChairmanFeb 22Buy10.054504,5225,350Feb 23 07:55 AM
Lamstein Joshua RChairmanFeb 19Buy10.935005,465116,697Feb 19 10:12 AM
Greenspan Ira ScottExecutive Committee ChairmanFeb 18Buy10.042,20022,0884,900Feb 18 09:22 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 17Buy9.812001,9622,700Feb 18 09:22 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 17Buy9.694754,60380,475Feb 18 09:22 PM
Greenspan Ira ScottExecutive Committee ChairmanFeb 16Buy10.202,50025,5002,500Feb 18 09:22 PM